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Abstract
Tumors in non-Hodgkin lymphoma (NHL) patients are often proximal to the major blood vessels in
the abdomen or neck. In external-beam radiotherapy, these tumors present a challenge because
imaging resolution prevents the beam from being targeted to the tumor lesion without also irradiating
the artery wall. This problem has led to potentially life-threatening delayed toxicity. Because
radioimmunotherapy has resulted in long-term survival of NHL patients, we investigated whether
the absorbed dose (AD) to the artery wall in radioimmunotherapy of NHL is of potential concern for
delayed toxicity. SPECT resolution is not sufficient to enable dosimetric analysis of anatomic features
of the thickness of the aortic wall. Therefore, we present a model of aortic wall toxicity based on
data from 4 patients treated with 131I-tositumomab.
Methods—Four NHL patients with periaortic tumors were administered pretherapeutic 131I-
tositumomab. Abdominal SPECT and whole-body planar images were obtained at 48, 72, and 144
h after tracer administration. Blood-pool activity concentrations were obtained from regions of
interest drawn on the heart on the planar images. Tumor and blood activity concentrations, scaled to
therapeutic administered activities—both standard and myeloablative—were input into a geometry
and tracking model (GEANT, version 4) of the aorta. The simulated energy deposited in the arterial
walls was collected and fitted, and the AD and biologic effective dose values to the aortic wall and
tumors were obtained for standard therapeutic and hypothetical myeloablative administered
activities.
Results—Arterial wall ADs from standard therapy were lower (0.6–3.7 Gy) than those typical from
external-beam therapy, as were the tumor ADs (1.4–10.5 Gy). The ratios of tumor AD to arterial
wall AD were greater for radioimmunotherapy by a factor of 1.9–4.0. For myeloablative therapy,
artery wall ADs were in general less than those typical for external-beam therapy (9.4–11.4 Gy for
3 of 4 patients) but comparable for 1 patient (32.6 Gy).
Conclusion—Blood vessel radiation dose can be estimated using the software package 3D-RD
combined with GEANT modeling. The dosimetry analysis suggested that arterial wall toxicity is
highly unlikely in standard dose radioimmunotherapy but should be considered a potential concern
and limiting factor in myeloablative therapy.
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During the last 40 y, dramatic improvements have been achieved in the treatment of lymphomas
(1), and although the life expectancy for a non-Hodgkin lymphoma (NHL) patient is less
favorable than that for a patient with Hodgkin disease (HD), significant clinical progress and
extended life expectancy is a reality today for both disease types. With improved survival,
concerns and issues related to long-term toxicity and quality of life of the survivors have
become crucial points of interest (1,2).
Although external-beam therapy is used more in HD, both chemotherapy and radiation may
cause short- and long-term side effects. In particular, arterial wall deterioration from external-
beam radiation is well documented (1–11); complications to the arteries can include arterial
stenosis (3), atherosclerosis, stroke (4), aneurysm, and coronary heart disease (5,6). Damage
has been clinically reported to all the major arteries: coronary (5,6), renal (7), aortic, femoral,
and carotid (6). Studies have shown the time frame for toxicity responses to be as early as 1 y
but more typically 10–20 y or more after treatment (1,6,8,9). Although initial postmortem
studies evoked 35 Gy of standard fractionated external-beam radiation as a limit for arterial
toxicity (10), increasing attention to long-term complications suggests lower thresholds (20–
25 Gy) (6), more in line with values considered toxic (~27 Gy) for other dose-limiting normal
organs such as kidneys (12), liver, and lungs (13). Until recently, arterial toxicity typically has
been considered only in cases of late complications and could be considered as a risk factor
only in atherosclerosis and related vascular complications along with other treatment- and
patient-related factors that affect the risk of late adverse outcomes, making estimation of
toxicity thresholds difficult.
To overcome the problems of toxicity (threshold determination intrinsic to long-term clinical
studies), animal studies have been conducted (14,15). In a mouse model, a single exposure of
14 Gy was sufficient to induce significant arterial damage (14). Although direct translation of
values from mouse to human is always questionable, this value merits attention.
Radioimmunotherapy, using anti-CD20 antibodies, has been approved as a treatment modality
for NHL. 131I-labeled tositumomab (Bexxar; GlaxoSmithKline) has shown good therapeutic
efficacy for patients with relapsed or refractory low-grade follicular NHL (16,17), as has 90Y-
ibrotumomab tiuxetan (Zevalin; Spectrum Pharmaceuticals, Inc.) (18,19). With the increasing
use of radioimmunotherapy as a viable treatment for NHL and the expected long-term survival
of these patients, knowledge of the arterial wall absorbed dose (AD) in cases in which the
disease sites are proximal to major blood vessels resulting from such treatment and the dose
to the vessel from the blood is essential, a fortiori, for therapeutic regimens with high
administered activities (AA). Myeloablative treatment, in which the administered activity is
based on dose limitations to normal organs other than bone marrow (20,21), is such a case.
To resolve this issue, recourse to standard dosimetric methodologies is insufficient, even those
typically used in patient-specific 3-dimensional (3D) dosimetry. SPECT or PET resolution is
not sufficient to enable standard dosimetric analysis of anatomic features of the thickness of
the aortic wall, nor is any imaging modality with its cubic lattice and large voxels able to
distinguish and define the artery walls. In this study, we have performed dosimetry on 4 patients
with periaortic tumors treated with 131I-tositumomab and unlabeled tositumomab and
calculated AD values to the aortic wall for both standard and myeloablative therapeutic AA
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by incorporating a Monte Carlo (MC)– based geometry and tracking model (GEANT, version
4) into the 3D-RD dosimetry software (22,23).
MATERIALS AND METHODS
Patients
Four patients of the 8 enrolled in an Institutional Review Board-approved NHL dose-response
protocol presented with noticeable tumors in the abdominal cavity. In particular, during
restaging with 18F-FDG PET/CT images (Fig. 1) the tumor masses circumscribed a large
portion of either the abdominal aorta or one or both femoral arteries. Patient clinical data
pertinent to this study are given in Table 1.
Data Acquisition
Each patient was administered approximately 200 MBq of 131I-tositumomab as a tracer.
Abdominal SPECT/CT scans taken on a Precedence SPECT/CT (16-slice; Philips) camera and
whole-body (WB) planar images acquired on a VG Millennium Hawkeye camera (GE
Healthcare) were acquired at 1 (WB only), 48, 72, and 144 h after tracer administration.
All the SPECT images were reconstructed using the quantitative SPECT (24) method (30
iterations, 16 subsets per iteration), based on the iterative ordered-subsets expectation
maximization algorithm (25) with reconstruction-based compensation for attenuation, scatter,
and the collimator–detector response function. The attenuation was modeled using measured
CT-based attenuation maps. Scatter compensation was performed using the effective source
scatter estimation method with a fast implementation. Point sources at various distances from
the face of the collimator were simulated to estimate the distance-dependent collimator–
detector response function that included interactions and penetration of photons in the
collimator and detector. Figure 2 illustrates examples of the SPECT reconstruction.
Therapeutic Activity Calculation
The standard therapeutic quantities of administered 131I activity were determined from the WB
tracer retention half-life calculated from WB images according to a protocol reported by Wahl
(26), using the WB dose limits given in Table 1. The WB dose limits (65 or 75 cGy) were
determined from the platelet counts of the patient shortly before administration of the
pretherapeutic activity. The calculated therapeutic activities for the 4 patients are given in Table
1.
3D-RD
The reconstructed images and the accompanying CT scans were registered on a HERMES
workstation (HERMES Medical Solutions) by registering CT to CT and then loaded into the
3D-RD software (22,23).
The 3 SPECT coregistered activity images and a coregistered CT scan were imported into the
3D-RD software package. Volumes of interest (VOIs) were drawn around the tumor and
selected major organs (lungs, liver, kidneys, spleen) in each patient, based on the CT images.
One million events were run for the β− and photon components of the 131I decay spectra based
on the SPECT images for each time point using electron γ-shower MC software. The energy
deposition distribution from the contributing components from MC were weighted for
probability and therapeutic activity and converted to absorbed dose rate for the VOIs (spectra
probability distributions obtained from the LBL/Lund web site (27)). The dose rates for the
different VOIs were fit with a hybrid trapezoid-exponential fit and integrated to obtain the AD.
Hobbs et al. Page 3
J Nucl Med. Author manuscript; available in PMC 2010 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Hypothetical Myeloablative Activity Calculation
To gauge the range of potential ADs to the artery walls from the most aggressive
radioimmunotherapy treatment plan available, hypothetical therapeutic AAs used in
myeloablative therapy were calculated using the guidelines established by the University of
Washington (21). The administered therapeutic activity was scaled to deliver no more than the
maximum tolerated dose (MTD), generally on the order of 27 Gy, to the most vulnerable organ
(excluding bone marrow), as determined by pretherapeutic dosimetry.
Geometric Model
The model for estimating the AD to the artery walls comprises 3 concentric cylinders created
in GEANT, representing the arterial contents (blood), artery wall, and the tumor. Figure 3
illustrates the model and many of the parameters used. The parameters for the arteries are taken
from the literature, and the parameters for the tumor are taken from the data. The volumes of
the tumors, V, were on the order of 300 g (261–424 g). A tumor thickness, rt, of 3 cm was used;
consequently, the height, h, was approximately 10 cm for each tumor. The internal radius of
the aorta, R, was given a value of 6.93 mm, and the thickness of the aorta wall, rw, was 1.15
mm (28). The parameter d in Figure 3 represents the range (2 cm) in the center of the model
for which the aortic wall AD would be the greatest and for which the average aortic wall AD
was calculated.
The second panel of Figure 3 represents a scenario with the same parameters for which the
tumor circumscribes only half (50%) of the vessel. In this scenario, the AD to the arterial wall
was calculated only in the half adjacent to the tumor.
Additionally, another set of scenarios was studied, namely for tumors surrounding smaller
arteries such as the femoral and carotid arteries. For these scenarios (for both 100% and 50%
enclosures), R was changed to 3.26 mm, rw became 0.91 mm (28), and rt was also modified to
1.5 cm, reflecting the smaller sizes of tumor seen in the PET images surrounding the smaller
arteries.
Kinetics
131I activity concentration for the tumors for each time point was obtained from the SPECT
images by dividing the measured activity by tumor volume, thus obtaining a uniform activity
concentration for the model. Blood-pool activity concentrations were obtained from the WB
images by drawing region-of-interest (ROI) contours around the heart, measuring the counts,
subtracting background counts from a scaled background ROI, converting to activity by scaling
to total AA divided by the total number of initial counts in the whole body, and dividing by a
typical heart volume (296 mL). Tumor and blood activity concentrations were plotted as a
function of time for each patient and integrated using either a simple exponential or a hybrid
trapezoid-exponential fit. The area under the curves was taken and multiplied by the blood or
tumor volume to obtain the respective cumulated activities for blood and tumor for each patient.
MC
GEANT MC simulations using 1 million decays were run separately for the tumor and blood
(as defined in the model shown in Fig. 3) for each of the following scenario combinations: the
aorta-sized vessel and tumor and the femoral artery-sized case, 50% and 100% enclosure
scenarios, and 131I and 90Y cases.
The deposited energy was collected for each time point in the arterial walls (only in the central
2 cm for all cases and only in the half wall adjacent to the tumor for the 50% enclosure
scenarios), the number of decays converted to units of cumulated activity, and the energy
divided by mass to obtain the S values for the different cases. The 90Y case was added, in
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consideration of the fact that the other radioimmunotherapeutic for NHL is 90Y-ibritumomab
tiuxetan. Although we recognized that 90Y-ibritumomab tiuxetan uptake, kinetics, and AAs
are different from those of 131I-tositumomab, rendering any direct dose comparison invalid, a
comparison of the S values between the 2 isotopes could be considered instructive. Thus, 90Y
was included in the MC portion of the model but not in the subsequent dosimetric calculations.
AD
The ADs for the artery walls were obtained by multiplying the cumulated activities by the S
values for the respective blood and tumor components and summing them. Additionally, a
whole-body contribution was added to the AD to the arteries, the rationale being that the
therapeutic AA is based on a limit on WB self-dose. This WB self-dose, which varies by patient
as a function of platelet count, must be considered in the final AD calculation. However, a
large fraction of the self-dose is from β emissions (57% as determined by calculating the photon
component of the 131I whole-body–to–whole-body S value by subtracting from it the total
electron energy emitted by 131I per decay divided by the whole-body mass), which are short-
ranged and were considered much more specifically using the MC input values. The missing
WB contribution was the longer-ranged photon component; consequently, 43% of the 65 or
75 cGy was added to the artery wall AD.
Radiobiology
In addition to the AD, 3D-RD incorporates radiobiologic modeling and calculates the biologic
effective dose (BED) for all tumors and normal organs, including the modeled arterial wall.
The BED (29,30) relates dose and dose rate to the biologic effect it will have and has been
shown to better predict normal-organ toxicity (12,31). The formula for the BED is:
Eq. 1
where α and β are the radiobiologic parameters from the linear quadratic model of cell survival
(32), D is the absorbed dose, and G(T) is the Lea-Catcheside G factor:
Eq. 2
where μ is the DNA repair constant, assuming exponential repair, and t and w are integration
variables. The α-to-β ratio for NHL was 8.6 Gy (33), and for the artery wall, a value of 3.0 Gy
was used (34). The repair rates typical for normal tissue (35) and tumor (36) used in this analysis
were 0.46 h−1 and 1.3 h−1, respectively. The BED was calculated for the tumor in 3D-RD and
for the aortic and arterial walls in the model using numeric integration (37). For external-beam
radiation the formula becomes:
Eq. 3
where d = D/N is the dose delivered per session, typically 2 Gy. The ratio between BED to the
tumor and BED to the artery wall is then:
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Eq. 4
RESULTS
Model Kinetics
The activity concentrations obtained for the blood from the WB planar images and for the
tumors from the SPECT images are plotted and shown in Figure 4. The blood curves were fit
with single exponential fits, and the tumor curves were fit with a single exponential for patients
2 and 3 only. Patient 1's tumor activity curve was fit with trapezoids to the last time point and
then allowed to decay physically. Patient 4's curve was fit with trapezoids for the first 2 time
points and then fit to an exponential calculated between the last 2 time points. The parameters
for the exponential fits are given in Table 2, where appropriate. The areas under the different
curves were calculated and multiplied by the appropriate volumes to obtain cumulated
activities.
MC
The simulated energy depositions from the different MC scenarios were converted into S
values, and the results are presented in Table 3.
AD
ADs to the artery walls were obtained as the product of the cumulated activities and the GEANT
model–derived S values. Tumor, liver, lung, and kidney ADs were calculated using 3D-RD.
The ADs to the latter 3 normal organs (values not shown) were used to determine the
myeloblative AAs.
The ADs for the artery walls are given in Table 4; they are divided into dose contributions from
whole-body photon emissions and from the total (electron and photon) contributions from the
blood and tumor. The 3D-RD-derived tumor ADs for patients 1–4 were 10.5, 1.44, 2.12, and
3.14 Gy, respectively. The corresponding GEANT-modeled tumor ADs were 10.5, 1.44, 2.63,
and 2.39 (simulated tumor ADs for other cases not shown).
Total ADs and BEDs are given in Table 5. The ratios between the AD to the (modeled) tumor
and the AD to the artery wall are also given.
BED
To calculate the BED, not only the AD value but also the kinetics must be known. By
multiplying the blood and tumor activities at the different time points by the appropriate S
values, the dose rate curves are obtained (Fig. 5). As expected, this figure resembles a linear
combination of the 2 graphs in Figure 4. The BED is calculated from these curves by numeric
integration; the results are presented in Table 5.
The conversion factor of AD to BED (Eq. 3) for external beam—assuming a single dose, d, of
2 Gy per patient visit—is 1.23 for the tumor and 1.67 for the artery wall. This represents a BED
range of 33–67 Gy to the artery wall and 25–49 Gy to the tumor for a typical range of external-
beam treatment (20–40 Gy).
Hobbs et al. Page 6
J Nucl Med. Author manuscript; available in PMC 2010 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Myeloablative BED
For administration of myeloablative activities, the ADs to both the tumor and artery walls are
simply multiplied by the multiplicative factor (therapeutic factor in Table 6). This factor was
determined by scaling the AD values for the potential dose-limiting organs (kidneys, liver, or
lungs) to the MTD and retaining the lowest scaling factor. The BEDs were recalculated
numerically from the increased dose rate values. Table 6 shows the BED values calculated for
myeloablative activities of 131I-tositumomab. For patient 1, the results in parentheses are those
that consider the artery wall to be the dose-limiting organ: the AA has been scaled to deliver
27 Gy of BED to the artery wall.
DISCUSSION
AD Comparison
The calculated ADs from standard 131I-tositumomab radioimmunotherapy to the arterial walls
were lower (0.60–3.71 Gy) than those typical from external-beam therapy (20–40 plus Gy) for
the 4 patients examined, using GEANT MC modeling and 3D-RD dosimetry. Moreover, the
typical artery AD is 1.9–4.0 times lower than the tumor dose in these worst-case scenarios
(tumor immediately adjacent to artery) modeled here and is below the range of values
considered as potentially toxic for fractionated external-beam therapy (20–35 Gy). For tumor
masses that are near although not immediately adjacent to the vessel wall, the ratio of tumor
dose to artery wall dose increases dramatically, resulting in even less potential long-term
toxicity. This is in contrast to external-beam therapy, for which improvements in radiation
technology such as intensity-modulated radiation therapy, designed to reduce the dose to
regions outside the targeted area, often fail to reduce the dose to proximal organs (38)—even
those that can be drawn and defined on the treatment planning, which certainly excludes artery
walls. The ratio of tumor dose to artery wall dose in those cases is effectively 1.0.
Myeloablative Therapy
The use of myeloablative therapy has proven to be successful (39,40), with limited toxicities
(20), although studies examining long-term (10–20 y) side effects have yet to be performed.
For 3 of 4 hypothetical treatments, arterial wall BED was below the standard 27 Gy of normal-
organ toxicity (9.7–12.5 Gy). For patient 1, including the artery wall in the list of potential
dose-limiting organs would have limited the AA to 20.5 GBq instead of 26.7 GBq, assuming
a limiting BED of 27 Gy, suggesting the utility of such an inclusion. The range of hypothetical
AAs calculated in the present study was higher (mean, 40.0 GBq; range, 26.7–70.6 GBq) than
for the published results (mean, 20.3 GBq; range, 9.6–42.7 GBq) (21). Those results, however,
used a range of MTD dose values (21–27 Gy) rather than a fixed 27 Gy, and the mean AA of
the present study was somewhat skewed by a single outlier (70.6 GBq), with a value unlikely
to be administered in a real clinical setting.
BED Comparison
Comparison with BED values is important in accounting for the differences in dose rates: the
BED to the arterial walls is 1.35 times greater than the BED to the tumor (ratio of 0.74) and
1.67 times more than the AD to the artery walls for external-beam therapy. This result is
dependent on the accuracy of the α/β values, which are determined for cell lines in vitro and
carry a significant degree of uncertainty; if the α/β value were lower for the tumor, this would
bring the BED ratio between tumor and artery wall closer to 1. Additionally, the BED values
to tumor and artery wall increase if the dose per fraction, d, in external-beam radiotherapy
increases. The ratio between AD and BED to the artery wall for d = 3 Gy increases from 1.67
to 2.0, resulting in a potential BED of 80 Gy to the artery wall for an AD of 40 Gy to a tumor
proximal to the artery. In contrast, the BEDs to the artery walls for the 4 patients in this study
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are 0.60–3.75 Gy. The ratios of tumor to artery wall BED are on the same order as the tumor-
to-artery wall AD ratios.
S Values
The S value comparison between 90Y and 131I reveals greater values for 90Y, about an order
of magnitude, particularly the values from the blood. This must be taken in context with the
relatively lower AA (approximately 3 times less) typical for 90Y-ibrotumomab tiuxetan therapy
with respect to 131I-tositumomab. Although the blood S values are fixed, the relative weight
of the tumor S values is likely to change as the distance between tumor and artery wall increases,
even for small distances (<1 cm).
The 50% cases have approximately twice the S value of the 100% cases because the artery
wall mass used in the calculations is only that adjacent to the tumor—that is, half that taken
for the 100% case. The relative significance of damage to a range of percentages of the
circumference of the artery wall is unclear yet obviously of great importance to the clinical
impact.
The source volumes for the blood-to-wall S values are those described in Figure 3 and not the
whole blood volume. The blood-to-artery wall S values are significantly larger than the tumor-
to-artery wall S values (Table 5). The AD results (Table 6), however, indicate a much greater
contribution from the tumor. This greater contribution is due to the much larger volume of the
tumor and, consequently, larger cumulated activity.
Scope and Limitations
The diameter used for the femoral artery is on a par with the diameters of the major arteries
under discussion in this study: carotid, renal, and coronary, and thus the AD values can be
considered reasonably relevant for all of these cases. The BED values depend on the accuracy
of the α/β values found in the literature. Clearly, a different value from the one used here could
influence the values calculated for the BED. A much higher value would dramatically reduce
the ratio between AD and BED for external-beam therapy and reduce the BED from radio-
immunotherapy slightly as well.
MC
This work illustrates a hybrid approach to AD calculations in situations where imaging cannot
resolve the potential dose-limiting structure. The use of MC with idealized geometries
overcomes the limitations of imaging-based dosimetry due to the finite resolving power of
SPECT or PET.
CONCLUSION
Long-term toxicity from radiation to the artery walls for patients treated for NHL is not a
concern with radioimmunotherapy, unlike for external-beam therapy. For myeloablative
administered activities, the ADs to the artery walls from periarterial tumors may be
commensurate with the lower end of toxic values; consequently, the artery wall should be
considered a potential dose-limiting organ.
Patient-specific, 3D-RD dosimetry, combined with MC modeling, can provide important and
more accurate dosimetry for anatomic features smaller than the imaging resolution.
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FIGURE 1.
Consecutive coronal 18F-FDG PET slices for restaging (patient 3).
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FIGURE 2.
Consecutive coronal slices of reconstructed SPECT images at 48 h for patient 3. CPS 5 counts
per second.
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FIGURE 3.
Geometric model of artery (red), arterial wall (green), and tumor (blue).
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FIGURE 4.
Model activity concentration kinetics in blood (left) and tumor (right) as determined from
patient data (WB scans and SPECT images, respectively).
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FIGURE 5.
Dose-rate plot for aortic model with 100% tumor enclosure and 131I-tositumomab.
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